New Drug Pricing Policy may be Decided by Middle of Next Month
The new National Pharmaceutical Pricing Policy will be decided by mid-November, the central government told the Supreme Court on Thursday.
The new National Pharmaceutical Pricing Policy will be decided by mid-November, the central government told the Supreme Court on Thursday.
‘The Justice Department officials are probing some drug pricing practices of Merck and Eli Lilly. Both the pharmaceutical companies said that they were cooperating with the probes.’
Tweet it Now
Elli Lilly's request for information came from the same US attorney's office. Lilly learned of the inquiry in September 2015. Lilly said, "Justice Department officials are conducting an inquiry concerning our treatment of certain distribution service agreements with wholesalers when calculating and reporting Average Manufacturer Prices in connection with the Medicaid drug rebate program." Both companies said that they were cooperating with the probes. These inquiries come as drug companies such as Valeant Pharmaceuticals International face higher scrutiny over drug pricing following accusations of predatory pricing.
Source-AFP
Unfair HIV-Drug Pricing Found in US Health Plans
Some US health insurance plans are placing antiretroviral drugs in a high-cost category, forcing the patients to pay more for coverage and discriminating against people with HIV, found a study.
Some US health insurance plans are placing antiretroviral drugs in a high-cost category, forcing the patients to pay more for coverage and discriminating against people with HIV, found a study.
Valeant Under US Federal Investigation Over Pricing of 2 Drugs Used for Cardiac Care
The pharmaceutical group says it has received subpoenas from US federal prosecutors seeking information about the pricing and distribution of its drugs.
The pharmaceutical group says it has received subpoenas from US federal prosecutors seeking information about the pricing and distribution of its drugs.
Embattled Drugmaker Valeant Pharmaceuticals Cuts Ties to Philidor RX
Valeant has lost confidence in Philidor's ability to continue to operate in a manner that is acceptable to Valeant and the patients and doctors we serve.
Valeant has lost confidence in Philidor's ability to continue to operate in a manner that is acceptable to Valeant and the patients and doctors we serve.
